Smith J A M, Amagasu S M, Hembrador J, Axt S, Chang R, Church T, Gee C, Jacobsen J R, Jenkins T, Kaufman E, Mai N, Vickery R G
Theravance Inc., 901 Gateway Blvd., South San Francisco, CA 94080, USA.
Mol Pharmacol. 2006 Mar;69(3):921-31. doi: 10.1124/mol.105.019257. Epub 2005 Dec 9.
The interaction of symmetrical lidocaine dimers with voltage-gated Na+ channels (VGSCs) was examined using a FLIPR membrane potential assay and voltage-clamp. The dimers, in which the tertiary amines of the lidocaine moieties are linked by an alkylene chain (two to six methylene units), inhibited VGSC activator-evoked depolarization of cells heterologously-expressing rat (r) Na(v)1.2a, human (h) Na(v)1.5, and rNa(v)1.8, with potencies 10- to 100-fold higher than lidocaine (compound 1). The rank order of potency (C4 (compound 4) > C3 (compound 3) > or = C2 (compound 2) = C5 (compound 5) = C6 (compound 6) >> compound 1) was similar at each VGSC. Compound 4 exhibited strong use-dependent inhibition of hNa(v)1.5 with pIC50 values < 4.5 and 6.0 for tonic and phasic block, respectively. Coincubation with local anesthetics but not tetrodotoxin attenuated compound 4-mediated inhibition of hNa(v)1.5. These data suggest that the compound 4 binding site(s) is identical, or allosterically coupled, to the local anesthetic receptor. The dissociation rate of the dimers from hNa(v)1.5 was dependent upon the linker length, with a rank order of compound 1 > compound 5 = compound 6 > compound 2 >> compound 3. The observation that both the potency and dissociation rate of the dimers was dependent upon linker length is consistent with a multivalent interaction at VGSCs. hNa(v)1.5 VGSCs did not recover from inhibition by compound 4. However, "chase" with free local anesthetic site inhibitors increased the rate of dissociation of compound 4. Together, these data support the hypothesis that compound 4 simultaneously occupies two binding sites on VGSCs, both of which can be bound by known local anesthetic site inhibitors.
使用荧光成像板读数器(FLIPR)膜电位测定法和电压钳技术研究了对称利多卡因二聚体与电压门控性钠离子通道(VGSCs)的相互作用。在这些二聚体中,利多卡因部分的叔胺通过亚烷基链(两到六个亚甲基单元)相连,它们抑制了VGSC激活剂诱发的异源表达大鼠(r)Na(v)1.2a、人(h)Na(v)1.5和rNa(v)1.8细胞的去极化,其效力比利多卡因(化合物1)高10到100倍。在每个VGSC上,效力的排序(C4(化合物4)> C3(化合物3)> 或 = C2(化合物2) = C5(化合物5) = C6(化合物6)>> 化合物1)相似。化合物4对hNa(v)1.5表现出强烈的使用依赖性抑制,强直和相性阻滞的pIC50值分别 < 4.5和6.0。与局部麻醉药而非河豚毒素共同孵育可减弱化合物4介导的对hNa(v)1.5的抑制。这些数据表明化合物4的结合位点与局部麻醉药受体相同或存在变构偶联。二聚体从hNa(v)1.5上的解离速率取决于连接链长度,排序为化合物1 > 化合物5 = 化合物6 > 化合物2 >> 化合物3。二聚体的效力和解离速率均取决于连接链长度这一观察结果与VGSCs上的多价相互作用一致。hNa(v)1.5 VGSCs未从化合物4的抑制中恢复。然而,用游离的局部麻醉药位点抑制剂“追赶”可增加化合物4的解离速率。总之,这些数据支持化合物4同时占据VGSCs上两个结合位点的假说,这两个位点均可被已知的局部麻醉药位点抑制剂结合。